Literature DB >> 2320575

Immunological properties of hepatitis B core antigen fusion proteins.

M J Francis1, G Z Hastings, A L Brown, K G Grace, D J Rowlands, F Brown, B E Clarke.   

Abstract

The immunogenicity of a 19 amino acid peptide from foot-and-mouth disease virus has previously been shown to approach that of the inactivated virus from which it was derived after multimeric particulate presentation as an N-terminal fusion with hepatitis B core antigen. In this report we demonstrate that rhinovirus peptide-hepatitis B core antigen fusion proteins are 10-fold more immunogenic than peptide coupled to keyhole limpet hemocyanin and 100-fold more immunogenic than uncoupled peptide with an added helper T-cell epitope. The fusion proteins can be readily administered without adjuvant or with adjuvants acceptable for human and veterinary application and can elicit a response after nasal or oral dosing. The fusion proteins can also act as T-cell-independent antigens. These properties provide further support for their suitability as presentation systems for "foreign" epitopes in the development of vaccines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320575      PMCID: PMC53726          DOI: 10.1073/pnas.87.7.2545

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg.

Authors:  D R Milich; A McLachlan; A Moriarty; G B Thornton
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

3.  Peptide vaccines based on enhanced immunogenicity of peptide epitopes presented with T-cell determinants or hepatitis B core protein.

Authors:  M J Francis; B E Clarke
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

4.  Antibody to hepatitis-B-virus core in man.

Authors:  J H Hoofnagle; R J Gerety; L F Barker
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

Review 5.  The common mucosal immune system and current strategies for induction of immune responses in external secretions.

Authors:  J Mestecky
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

6.  The detection of viruses by enzyme-linked immunosorbent assay (ELISA).

Authors:  A Voller; A Bartlett; D E Bidwell; M F Clark; A N Adams
Journal:  J Gen Virol       Date:  1976-10       Impact factor: 3.891

7.  New antigen-antibody system in Australia-antigen-positive hepatitis.

Authors:  J D Almeida; D Rubenstein; E J Stott
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

8.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen.

Authors:  D R Milich; A McLachlan
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

9.  Hepatitis B virus genes and their expression in E. coli.

Authors:  M Pasek; T Goto; W Gilbert; B Zink; H Schaller; P MacKay; G Leadbetter; K Murray
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

10.  Immunochemistry and polypeptide composition of hepatitis B core antigen (HBc Ag).

Authors:  A Budkowska; J W Shih; J L Gerin
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

View more
  14 in total

1.  The affinities of monoclonal antibodies against core antigen of hepatitis B virus.

Authors:  U Apsalons; V Bichko
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model.

Authors:  T Cao; U Lazdina; I Desombere; P Vanlandschoot; D R Milich; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen.

Authors:  R Ulrich; G P Borisova; E Gren; I Berzin; P Pumpen; R Eckert; V Ose; H Siakkou; E J Gren; R von Baehr
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein.

Authors:  A Yoshikawa; T Tanaka; Y Hoshi; N Kato; K Tachibana; H Iizuka; A Machida; H Okamoto; M Yamasaki; Y Miyakawa
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

Review 5.  Use of hepadnavirus core proteins as vaccine platforms.

Authors:  David C Whitacre; Byung O Lee; David R Milich
Journal:  Expert Rev Vaccines       Date:  2009-11       Impact factor: 5.217

6.  Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle.

Authors:  C S Brown; T Jensen; R H Meloen; W Puijk; K Sugamura; H Sato; W J Spaan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles.

Authors:  S J Harris; A J Gearing; G T Layton; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

8.  Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies.

Authors:  A M Roseman; O Borschukova; J A Berriman; S A Wynne; P Pumpens; R A Crowther
Journal:  J Mol Biol       Date:  2012-06-28       Impact factor: 5.469

9.  Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins.

Authors:  Hadrien Peyret; Annick Gehin; Eva C Thuenemann; Donatienne Blond; Aadil El Turabi; Lucy Beales; Dean Clarke; Robert J C Gilbert; Elizabeth E Fry; David I Stuart; Kris Holmes; Nicola J Stonehouse; Mike Whelan; William Rosenberg; George P Lomonossoff; David J Rowlands
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

Review 10.  Self-assembling protein nanoparticles in the design of vaccines.

Authors:  Jacinto López-Sagaseta; Enrico Malito; Rino Rappuoli; Matthew J Bottomley
Journal:  Comput Struct Biotechnol J       Date:  2015-11-26       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.